OBJECTIVES: To evaluate the safety and efficacy of a new liquid embolic agent in brain arteriovenous malformation (bAVMs) embolisation. METHODS: A prospective, multicentre series was conducted at 11 interventional centres in Europe to evaluate embolisation of bAVMs with the new liquid embolic agent. Technical conditions, complications, clinical outcome and anatomical results were independently analysed. RESULTS: From December 2005 to December 2008, 117 patients (72 male; 45 female, aged 18-75 years) were included. Clinical presentation was mostly haemorrhage (34.2 %) and seizures (28.2 %). Most AVMs were located in the brain hemispheres (85.5 %). AVMs were <3 cm in 52.1 % of patients and ≥ 3 cm in 47.9 %. Morbidity was observed in 6/117 patients (5.1 %), related to haemorrhagic events in 2 cases and non-haemorrhagic complications in 4 cases. Five patients (4.3 %) died in relation to the treatment (bleeding in 4 patients and extensive venous thrombosis in 1). Complete occlusion of the AVM by embolisation alone was obtained in 23.5 % of patients. Complementary treatment was performed in 82.3 % of patients with partial AVM occlusion, mostly radiosurgery. CONCLUSIONS: In this prospective, multicentre, European, observational series, the new liquid embolic agent proved to be suitable for BAVM embolisation, with acceptable morbidity and mortality and good efficacy. KEY POINTS: • Numerous interventional techniques have been used to embolise brain arteriovenous malformations (AVMs). • This prospective multicentre study demonstrates the suitability of a liquid embolic agent. • The safety of treatment using Onyx is acceptable. • Such embolisation leads to complete AVM occlusion in 23.5 % of patients.
OBJECTIVES: To evaluate the safety and efficacy of a new liquid embolic agent in brain arteriovenous malformation (bAVMs) embolisation. METHODS: A prospective, multicentre series was conducted at 11 interventional centres in Europe to evaluate embolisation of bAVMs with the new liquid embolic agent. Technical conditions, complications, clinical outcome and anatomical results were independently analysed. RESULTS: From December 2005 to December 2008, 117 patients (72 male; 45 female, aged 18-75 years) were included. Clinical presentation was mostly haemorrhage (34.2 %) and seizures (28.2 %). Most AVMs were located in the brain hemispheres (85.5 %). AVMs were <3 cm in 52.1 % of patients and ≥ 3 cm in 47.9 %. Morbidity was observed in 6/117 patients (5.1 %), related to haemorrhagic events in 2 cases and non-haemorrhagic complications in 4 cases. Five patients (4.3 %) died in relation to the treatment (bleeding in 4 patients and extensive venous thrombosis in 1). Complete occlusion of the AVM by embolisation alone was obtained in 23.5 % of patients. Complementary treatment was performed in 82.3 % of patients with partial AVM occlusion, mostly radiosurgery. CONCLUSIONS: In this prospective, multicentre, European, observational series, the new liquid embolic agent proved to be suitable for BAVM embolisation, with acceptable morbidity and mortality and good efficacy. KEY POINTS: • Numerous interventional techniques have been used to embolise brain arteriovenous malformations (AVMs). • This prospective multicentre study demonstrates the suitability of a liquid embolic agent. • The safety of treatment using Onyx is acceptable. • Such embolisation leads to complete AVM occlusion in 23.5 % of patients.
Authors: J J Bhattacharya; S Jenkins; P Zampakis; M Behbahani; E Teasdale; V Papanastassiou Journal: Interv Neuroradiol Date: 2005-10-27 Impact factor: 1.610
Authors: Yuri M Andrade-Souza; Meera Ramani; Daryl Scora; May N Tsao; Karel terBrugge; Michael L Schwartz Journal: Neurosurgery Date: 2007-03 Impact factor: 4.654
Authors: J P Mohr; Alan J Moskowitz; Christian Stapf; Andreas Hartmann; Karen Lord; Steven M Marshall; Henning Mast; Ellen Moquete; Claudia Scala Moy; Michael Parides; John Pile-Spellman; Rustam Al-Shahi Salman; Alan Weinberg; William L Young; Alejandrina Estevez; Inam Kureshi; Jonathan L Brisman Journal: Stroke Date: 2010-07-15 Impact factor: 7.914
Authors: Adnan I Qureshi; Nidaullah Mian; Harris Siddiqi; Mushtaq H Qureshi; Adil M Malik; Mohammad Rauf Afzal; Asif A Khan; M Fareed K Suri Journal: J Vasc Interv Neurol Date: 2015-07
Authors: L H de Castro-Afonso; G S Nakiri; R S Oliveira; M V Santos; A C Dos Santos; H R Machado; D G Abud Journal: Neuroradiology Date: 2016-02-24 Impact factor: 2.804
Authors: Dominik F Vollherbst; Ruth Otto; Thuy Do; Hans U Kauczor; Martin Bendszus; Christof M Sommer; Markus A Möhlenbruch Journal: Interv Neuroradiol Date: 2018-07-04 Impact factor: 1.610
Authors: Karla M Treitl; Michael Scherr; Monika Förth; Franziska Braun; Daniel Maxien; Marcus Treitl Journal: Eur Radiol Date: 2014-10-16 Impact factor: 5.315
Authors: W Caleb Rutledge; Adib A Abla; Jeffrey Nelson; Van V Halbach; Helen Kim; Michael T Lawton Journal: Neurosurg Focus Date: 2014-09 Impact factor: 4.047